Senior Adviser, Ignition
| Role | Organisation | Sources |
|---|---|---|
| GBS Venture Partners Ltd. | clinicalleader.com | |
| Chairman (former) | Spinifex Pharmaceuticals | GBS Ventures, clinicalleader.com |
| Global Partner (former) | NMG Consulting | Australian FinTech |
| Head of Proposition, Product & Strategy (former) | AustralianSuper | Australian FinTech |
| Partner (former) | GBS Ventures | GBS Ventures, GBS Ventures team page |
| Senior Adviser | Ignition | Australian FinTech |
Stories naming Dr Andrew Baker. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Ignition hires Andrew Baker as Senior Adviser to advise on Asia Pacific and global pension strategy. He previously founded Tria Investment Partners and held roles at NMG Consulting and AustralianSuper.
GBS Ventures marks its fourth FDA drug approval as Hatchtech's head lice treatment Xeglyze clears the regulator, recalling earlier wins behind Picato, Synribo and Aridol with Australian biotech firms.
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·novartis.com·clinicalleader.com·Brandon Capital portfolio·Startup Daily·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia